[Update on beta blockers in 2020].

La Revue de médecine interne
T Bejan-Angoulvant, D Angoulvant

Abstract

Beta-blockers (BB) are an heterogenous set of molecules actively blocking β adrenergic receptors. Their pharmacological properties depend on their various effects on the adrenergic signalling. Although they are no longer a first-choice treatment in hypertensive patients, they remain a cornerstone of pharmacological strategy in several cardiovascular diseases such as stable angina, heart failure, arrythmia and aortic related connective diseases. Beyond their usual non cardiovascular indications such as migraine, hepatic cirrhosis, glaucoma, infantile hemangioma, and hyperthyroidism, new therapeutic fields are under scrutiny. Potential BB therapeutic repurposing is being investigated in COPD and cancer patients. This narrative review first encompasses the basic pharmacological knowledge that may be useful for the clinician. Then it will detail BB main indications before exploring new therapeutic fields.

References

Jun 25, 1999·BMJ : British Medical Journal·N FreemantleJ Harrison
Jun 2, 2001·The New England Journal of Medicine·M PackerUNKNOWN Carvedilol Prospective Randomized Cumulative Survival Study Group
Jun 27, 2002·Clinical Pharmacokinetics·William H Frishman, Mamata Alwarshetty
Jul 16, 2002·JAMA : the Journal of the American Medical Association·Dennis T KoHarlan M Krumholz
Aug 28, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·S EversUNKNOWN European Federation of Neurological Societies
Sep 9, 2010·Cancer Research·Erica K SloanSteven W Cole
Mar 1, 2012·Journal of the American College of Cardiology·Ingrid KindermannMichael Böhm
Aug 23, 2012·Orphanet Journal of Rare Diseases·Estelle DesportUNKNOWN Centre national de référence pour l’amylose AL et les autres maladies par dépôts d’immunoglobulines monoclonales
Jul 5, 2013·European Heart Journal·Alida L P CaforioUNKNOWN European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
Oct 2, 2014·Circulation. Cardiovascular Quality and Outcomes·Sripal BangaloreA Michael Lincoff
Feb 19, 2015·The New England Journal of Medicine·Christine Léauté-LabrèzeJean-Jacques Voisard
Apr 4, 2016·Lancet·Simone De LeoLewis E Braverman
Jul 9, 2016·The European Respiratory Journal·Brian LipworthMark T Dransfield
Aug 28, 2016·European Heart Journal·Paulus KirchhofUNKNOWN ESC Scientific Document Group
Oct 1, 2016·Pediatrics·Christine Léaute-LabrèzeJean-Jacques Voisard
Jun 1, 2017·Hypertension·Tetsuro TsujimotoHiroshi Kajio
Jul 26, 2017·Cardiology in Review·James J NawarskasWilliam H Frishman
Sep 10, 2017·European Heart Journal·Helmut BaumgartnerUNKNOWN ESC Scientific Document Group
Apr 28, 2018·Journal of the American College of Cardiology·Sofia ChatzidouStylianos Rokas
May 31, 2018·Current Opinion in Pediatrics·Rachael HagenZachary Zinn
Aug 31, 2018·European Heart Journal·Bryan WilliamsUNKNOWN ESC Scientific Document Group
Sep 29, 2018·Journal of the American College of Cardiology·Gisela Teixido-TuraArtur Evangelista
Sep 30, 2018·The Journal of Clinical Hypertension·Lewei DuanMing-Sum Lee
Feb 25, 2019·Life Sciences·Khushwant S YadavSushmita Sharma
Apr 20, 2019·Journal of the American College of Cardiology·Michael FrankXavier Jeunemaitre
May 18, 2019·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Eleonora Grandi, Crystal M Ripplinger
Aug 3, 2019·Alimentary Pharmacology & Therapeutics·Tammo L TergastBenjamin Maasoumy
Sep 11, 2019·European Heart Journal·Juhani KnuutiUNKNOWN ESC Scientific Document Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Related Papers

Casopís lékar̆ů c̆eských
J Spinar, J Vítovec
Diabetes/metabolism Reviews
J P MordesA A Rossini
© 2022 Meta ULC. All rights reserved